Earendil Labs and WuXi Biologics Partner to Accelerate Bispecific and Multispecific Antibody Development

The strategic collaboration aims to advance Earendil Labs' pipeline of next-generation biologics through WuXi Biologics' expertise in complex drug manufacturing.

Mar. 12, 2026 at 2:00pm

Got story updates? Submit your updates here. ›

Earendil Labs, an AI-driven biotech company, and WuXi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO), have announced a strategic collaboration to accelerate the development and manufacturing of Earendil Labs' pipeline of bispecific and multispecific antibodies and antibody-drug conjugates (ADCs) targeting autoimmune diseases, cancer, and other conditions.

Why it matters

The partnership combines Earendil Labs' AI-powered protein engineering capabilities with WuXi Biologics' proven expertise in developing and manufacturing complex biologics. This integration is expected to enhance the speed, quality, and scalability of Earendil Labs' pipeline as it advances towards clinical milestones and potential commercialization.

The details

Under the agreement, WuXi Biologics will provide end-to-end biologics development and manufacturing services for Earendil Labs, including cell line development, process and bioassay development, drug product formulation, and GMP manufacturing. WuXi Biologics has built a strong track record in bispecific and multispecific antibodies, as well as ADCs, leveraging its technology platforms and expanded capabilities for high-dose and subcutaneous delivery.

  • The strategic collaboration was announced on March 12, 2026.

The players

Earendil Labs

An AI-powered biotech company focusing on researching and developing next-generation innovative biologics for the treatment of autoimmune, cancer, and other diseases.

WuXi Biologics

A global leading Contract Research, Development and Manufacturing Organization (CRDMO) that provides end-to-end biologics development and manufacturing services.

Jian Peng, PhD

CEO of Earendil Labs.

Zhenping Zhu, MD, PhD

President & co-CEO of Earendil Labs.

Chris Chen, PhD

CEO of WuXi Biologics.

Got photos? Submit your photos here. ›

What they’re saying

“Partnering with WuXi Biologics enables us to advance our pipeline with greater speed, precision, and CMC excellence. By integrating Earendil Labs' AI-driven protein‑engineering capabilities with WuXi Biologics' deep expertise in complex biologics as well as its proven end‑to‑end development and manufacturing capabilities, we can more efficiently advance our pipeline toward clinical milestones to deliver meaningful clinical benefit and transform patient treatment.”

— Jian Peng, PhD, CEO of Earendil Labs

“Earendil Labs has built a robust and highly competitive pipeline within the past three years. This partnership with WuXi Biologics strengthens our ability to translate AI-driven innovation into high-quality clinical and commercial assets. WuXi Biologics' proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset therapeutic pipeline for the treatment of various human diseases.”

— Zhenping Zhu, MD, PhD, President & co-CEO of Earendil Labs

“We are delighted to enter this strategic collaboration with Earendil Labs, a company distinguished by its strong scientific leadership and innovative approach to advancing next‑generation immunotherapies. By leveraging our proven expertise across complex biologics—including bispecific and multispecific antibodies as well as ADCs—and our industry‑leading technology platforms across drug research, development and manufacturing, we aim to accelerate the advancement of Earendil Labs' innovative pipeline. Through this collaboration, we are poised to accelerate development, ensure robust and scalable manufacturing, and ultimately bring transformative therapies to patients worldwide.”

— Chris Chen, PhD, CEO of WuXi Biologics

What’s next

The collaboration is designed to accelerate regulatory timelines, enhance CMC execution reliability, and support scalable global clinical development across Earendil Labs' programs.

The takeaway

This strategic partnership between Earendil Labs and WuXi Biologics leverages the strengths of both companies to drive the development of innovative bispecific and multispecific antibodies and ADCs, with the potential to deliver transformative therapies for patients with autoimmune diseases, cancer, and other unmet medical needs.